Antimycotics are the most frequently applied group of remedies in dermatology. They are applied locally as well as systemically. Their systemic application is connected with the risk of mutual interactions with other simultaneously applied drugs. Such risk is greater namely in patients with several diseases, who take many remedies. In such patients the weakened immune function predisposes them to mycotic infection. Antimycotics have a marked interactive potential because they are able to inhibit cytochrome P450 isoenzymes which largely participate in the metabolism of other xenobiotics. The slowing down of biotransformation can lead to cumulation of drugs in the organism and to the manifestation of adverse effects. On the other hand, the pharmacokinetics of antimycotics can be influenced by other drugs, namely by substances capable of accelerating their metabolismby the induction of biotransformation enzymes. The basic prerequisite for preventing interactions is a high level of the physician’s knowledge about combinations under risk. Presented is a review of clinically important interactions of azole antimycotics and terbinafin.

        Key words: azole antimycotics - terbinafin - interaction - enzyme inhibition - enzyme induction